[
    [
        {
            "time": "",
            "original_text": "上海莱士：目前，郑州莱士已获得静注人免疫球蛋白（PH4）《药品补充申请批准通知书》，后续河南省食品药品监督管理局将对上述项目的生产现场进行核查，获得批准后，郑州莱士静注人免疫球蛋白生产线可恢复生产",
            "features": {
                "keywords": [
                    "郑州莱士",
                    "静注人免疫球蛋白",
                    "药品补充申请批准通知书",
                    "恢复生产"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "上海莱士：目前，郑州莱士已获得静注人免疫球蛋白（PH4）《药品补充申请批准通知书》，后续河南省食品药品监督管理局将对上述项目的生产现场进行核查，获得批准后，郑州莱士静注人免疫球蛋白生产线可恢复生产",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        }
    ]
]